[EN] SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS [FR] COMPOSÉS AMINOPYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS D'EGFR
摘要:
The present invention provides novel aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
[EN] 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES FUSIONNÉS 6,6 EN TANT QU'INHIBITEURS DE METTL3
申请人:[en]858 THERAPEUTICS, INC.
公开号:WO2023129933A2
公开(公告)日:2023-07-06
The present disclosure relates to 6,6-fused heterocyclic compounds and related compounds and their use in treating a disease or condition responsive to modulation or inhibition of METTL3.
[EN] SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS<br/>[FR] COMPOSÉS AMINOPYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS D'EGFR
申请人:[en]YUHAN CORPORATION
公开号:WO2023027518A1
公开(公告)日:2023-03-02
The present invention provides novel aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.